Winters Chad 4
Research Summary
AI-generated summary
West Pharmaceutical (WST) VP Chad Winters Receives Restricted Stock Awards
What Happened
Chad Winters, Vice President and Chief Accounting Officer of West Pharmaceutical Services (WST), was granted two awards of restricted stock units (RSUs) on 2026-03-01: 340 RSUs and 808 RSUs, for a total of 1,148 RSUs. The transaction is reported as derivative awards with an acquisition price of $0.00 (typical for RSU grants); no cash was exchanged and no immediate shares were issued.
Key Details
- Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (appears timely).
- Awards: 340 RSUs and 808 RSUs (total 1,148 RSUs); price shown as $0.00.
- Vesting: The RSUs vest in four equal annual installments beginning March 1, 2027 (per filing footnote).
- Shares owned after transaction: not specified in the provided filing details.
- Footnotes: F1 clarifies each RSU equals a contingent right to one share; F2 gives the four-year vesting schedule; F3 notes a standard four-year option vesting schedule but no stock option transaction is reported here.
- Transaction type: Award/Grant (code A) — not a market purchase or sale.
Context
RSUs are compensation awards that convert to actual shares only as they vest; they do not represent an immediate open‑market purchase or sale. Such grants are routine executive compensation and should be viewed as part of pay/retention programs rather than a direct buy/sell signal.